ioxilan ioxilan ioxilan is a diagnostic contrast agent. it is injected intravenously before taking x-ray images to increase arterial contrast in the final image. it was marketed in the us under the trade name oxilan by guerbet, l.l.c., but has been discontinued in 2017. ioxilanclinical datatrade namesoxilanahfs/drugs.comfda professional drug informationroutes ofadministrationintravenouslyatc codev08ab12 (who) legal statuslegal status us: ℞-only discontinued pharmacokinetic databioavailabilityn/aprotein bindingnegligiblemetabolismnoneelimination half-life2 hoursexcretionmostly renalidentifiers iupac name 1-n-(2,3-dihydroxypropyl)-5--3-n-(2-hydroxyethyl)-2,4,6-triiodobenzene-1,3-dicarboxamide cas number107793-72-6 npubchem cid3743drugbankdb09135 ychemspider3612 yuniia4yj7j11tgkeggd02161 ychemblchembl1201075 ncomptox dashboard (epa)dtxsid0048717 chemical and physical dataformulac18h24i3n3o8molar mass791.112 g·mol−13d model (jsmol)interactive image smiles o=c(n(c1c(i)c(c(i)c(c1i)c(=o)ncco)c(=o)ncc(o)co)cc(o)co)c inchi inchi=1s/c18h24i3n3o8/c1-8(28)24(5-10(30)7-27)16-14(20)11(17(31)22-2-3-25)13(19)12(15(16)21)18(32)23-4-9(29)6-26/h9-10,25-27,29-30h,2-7h2,1h3,(h,22,31)(h,23,32) ykey:uumltinzbqpngf-uhfffaoysa-n y ny (what is this?) (verify) mechanism of action ioxilan is an iodinated contrast agent.